Protagenic TherapeuticsPTIX
13F holders, Q2 2024 (June 30)11holders
2new positions
2sold out
$0.91avg. 13F price*
At the end of Q2 2024, 11 institutions reported holding Protagenic Therapeutics Inc. (PTIX) in their 13F filings, unchanged from Q1 2024. 2 opened new positions and 2 sold out. The largest holders were Vanguard Group Inc. ($30K), Geode Capital Management, LLC ($27K) and Susquehanna International Group, LLP ($24K).
- Company
- Protagenic Therapeutics Inc.
- CUSIP
- 74365N202
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $34K |
| Exits | 2 | $11.9M |
All 13F filers, Q1 2024 → Q2 2024: 41,653 shares bought and 419,351 shares sold, net −377,698 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Vanguard Group Inc. | 0.00% | No change | 33,166 | $30K |
| Geode Capital Management, LLC | 0.00% | Add +15.7% | 29,130 | $27K |
| Susquehanna International Group, LLP | 0.00% | New | 26,598 | $24K |
| Osaic Holdings, Inc. | 0.00% | No change | 21,414 | $19K |
| FNY Investment Advisers, LLC | 0.01% | No change | 18,750 | $17K |
| State Street Corp. | 0.00% | No change | 13,812 | $13K |
| UBS Group AG | 0.00% | New | 10,078 | $9K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +17.1% | 6,806 | $6K |
| Bank of America Corp. | 0.00% | Add +2800.0% | 29 | $26 |
| Morgan Stanley | 0.00% | No change | 1 | $1 |
| Cwm, LLC | 0.00% | No change | 1 | $0 |
"% of holder's portfolio" is PTIX's weight in each manager's 13F, not the share of Protagenic Therapeutics Inc. the manager owns.